Homepage SA

Sarepta Therapeutics receives accelerated approval for Duchenne muscular dystrophy drug.
Read the press release to learn more.
 
 
 

THE PROMISE OF SCIENCE, REALIZED™

We are Sarepta Therapeutics: a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. Our primary focus is on rapidly advancing the development of our potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.

Dedicated Patient Support

Our commitment to the patients and families
impacted by Duchenne muscular dystrophy
extends beyond treatment. We are proud to offer
SareptAssist™, a patient support program
for those seeking information on therapy.

TRANSFORMATION, WITHIN REACH™

Our unique RNA-based technology has
the potential to advance treatments in
numerous areas of high unmet need. We are
continuing to advance our clinical
programs for Duchenne muscular dystrophy.

TURNING DISCOVERY INTO RECOVERY™

We seek collaborations with leaders in industry,
government, and academia to make meaningful
advances in medicine. Our proprietary and
highly versatile RNA-targeted technologies form the
foundation of our partnering strategy.